摘要
本研究旨在评估阿尔茨海默病(AD)的神经精神性症状和区域灰质(GM)在使用基于体素的形态学测量(VBM)方法下的关系。从阿尔茨海默病神经影像学准则下选择85例AD患者的数据,208名轻度认知障碍(MCI)和131例健康对照组。个人VBM模型的整个样本中神经精神量表问卷的每个项目为变量,四个协变量为规定值,包括年龄、性别、颅内总体积(TIV)、简易精神状态检查(MMSE)评分。激越症状与左额叶、岛叶和双侧扣带皮质GM萎缩相关。运动行为异常(AMB)与右侧基底节区GM萎缩有关。VBM模型进行指定三个协变量(年龄,性别,TIV),不包括由MMSE标记AD严重程度相关的体素。该过程确认了第一个结果,并显示抑郁症和左额中回灰质萎缩之间的关联,激越症状和左侧额叶皮质GM萎缩相关,AMB与右下额叶皮质GM萎缩相关。分层多元回归分析使用这些额外的区域中提取的平均值证实了这些关联。最后,群组内(85例AD和41例MCI)VBM分析在一定程度上确认了结果。我们的研究结果表明,在AD相关的神经退行性疾病中GM萎缩的特异性模式诱发某些特定的神经精神症状,表明了不同的神经生物学机制。
关键词: 运动行为异常,激越,阿尔兹海默病,抑郁症,轻度认知障碍,神经精神症状,基于体素的形态学测量
Current Alzheimer Research
Title:Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease
Volume: 12 Issue: 3
Author(s): Xiaochen Hu, Dix Meiberth, Beate Newport, Frank Jessen and the Alzheimer’s Disease Neuroimaging Initiative
Affiliation:
关键词: 运动行为异常,激越,阿尔兹海默病,抑郁症,轻度认知障碍,神经精神症状,基于体素的形态学测量
摘要: The current study aimed to assess the relationship between the neuropsychiatric symptoms in Alzheimer’s disease (AD) and the regional grey matter (GM) volume using voxel based morphometry (VBM). Data of 85 AD patients, 208 subjects with mild cognitive impairment (MCI), and 131 healthy controls were selected from the Alzheimer’s Disease Neuroimaging Initiative. Individual VBM models across the entire sample for each items of the Neuropsychiatric Inventory Questionnaire as variables of interest were specified with four nuisance covariates, including age, sex, total intracranial volume (TIV), and Mini-Mental State Examination (MMSE) score. Agitation was related to the GM atrophy in the left inferior frontal/insula and bilateral retrosplenial cortices. Aberrant motor behavior (AMB) was related to the GM reductions in the right basal ganglia. The VBM models were recalculated by specifying three nuisance covariates (age, sex, TIV), and by excluding voxels related to AD severity by applying a MMSE mask. This procedure confirmed the first results, and additionally revealed associations between depression and GM atrophy in the left middle frontal cortex, between agitation and the GM atrophy in the left middle frontal cortex, and between AMB and GM reduction in the right inferior frontal cortex. Hierarchical multiple regression analyses using extracted mean GM value in these additional regions confirmed these associations. Finally, VBM analyses within a subgroup (85 AD patients and 41 MCI converters) largely confirmed the results. Our results suggest that specific patterns of GM atrophy within AD related neurodegeneration predispose to certain neuropsychiatric symptoms, suggesting distinct neurobiological mechanisms.
Export Options
About this article
Cite this article as:
Xiaochen Hu, Dix Meiberth, Beate Newport, Frank Jessen and the Alzheimer’s Disease Neuroimaging Initiative , Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302154914
DOI https://dx.doi.org/10.2174/1567205012666150302154914 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Miniaturization and Validation of the Ellmans Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format and Screening of a Chemical Library
Combinatorial Chemistry & High Throughput Screening Metabolism of Selegiline [(-)-Deprenyl)]
Current Medicinal Chemistry The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Towards Alzheimers Disease Vaccination
Mini-Reviews in Medicinal Chemistry Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study
Current Pharmaceutical Design Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer’s Disease and Other Inflammation-related Pathologies
Current Alzheimer Research When Nutraceuticals Reinforce Drugs Side Effects: A Case Report
Current Drug Safety Amyloid Aggregation Inhibitory Mechanism of Arginine-rich D-peptides
Current Medicinal Chemistry Untangling Alzheimer’s Disease Clinicoanatomical Heterogeneity Through Selective Network Vulnerability – An Effort to Understand a Complex Disease
Current Alzheimer Research Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Biochemical Differentiation of Cholinesterases from Normal and Alzheimers Disease Cortex
Current Alzheimer Research Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology